


Claims:

1. Combination which comprises nateglinide (I)



and (a) an antidiabetic phenylacetic acid derivative or (b) acarbose in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

2. Combination according to claim 1 which is a combined preparation or a pharmaceutical composition.

3. Combination according to claim 2 which is a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of diseases.

4. Combination according to any one of claims 1 to 3 wherein the combination comprises the antidiabetic phenylacetic acid derivative repaglinide or a pharmaceutically acceptable salt thereof.

5. Combination according to any one of claims 1 to 3, characterized in that the combination comprises acarbose.

6. Combination according to any one of claims 1 to 5, characterized in that the combination comprises at least one further pharmaceutically active compound selected from the group consisting of antidiabetic thiazolidinediones, sulphonyl urea derivatives, metformin, and insulin, or the pharmaceutically acceptable salts of such compounds where possible; or at least one further antidiabetic phenylacetic acid derivative or a pharmaceutically acceptable salt thereof.

7. Combination according to any one of claims 1 to 6, characterized in that nateglinide is present in the B-type or H-type crystal modification.
8. Method of improving the bodily appearance of a mammal which comprises orally administering to said mammal a combination according to any one of claims 1 to 7 in a dosage effective to influence the glucose metabolism, and repeating said dosage until a cosmetically beneficial loss of body weight has occurred.
9. Method of treatment of a warm-blooded animal having metabolic disorders comprising administering to the animal a combination of nateglinide and (a) an antidiabetic phenylacetic acid derivative or (b) acarbose in a quantity which is jointly therapeutically effective against metabolic disorders in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
10. A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against metabolic disorders, of a combination according to any one of claims 1 to 7, and at least one pharmaceutically acceptable carrier.
11. Use of a combination according to any one of claims 1 to 7 for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders.
12. Use of a combination according to any one of claims 1 to 7 for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.
13. A commercial package comprising as active agent nateglinide and (a) an antidiabetic phenylacetic acid derivative or (b) acarbose, together with instructions for simultaneous, separate or sequential use thereof in the prevention, delay of progression or treatment of metabolic disorders or in a method of improving the bodily appearance of a mammal.